Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center

Bharadwaz, Arindam; Bak-Fredslund, Kirstine; Villadsen, Gerda Elisabeth; Simonsen, Kira; Sandahl, Thomas Damgaard; Grønbæk, Henning; Nielsen, Dorte Guldbrand

doi:10.1177/0284185115603246

Cited by 7 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we are now conducting a study in which the role of CLIPS and JIS scoring systems is elucidated in stratifying the patients with HCC who are strictly at BCLC stage B in our patient population. Finally, the etiology of HCC, and its treatment strategies as well, is different in different countries (2), and therefore, our results may not be generalized or directly applicable to patients in other parts of the world.…”

Section: Discussionmentioning

confidence: 89%

“…Hepatocellular carcinoma (HCC) mainly involves patients already affected with chronic hepatitis or liver cirrhosis due to hepatitis B or C viral infection (1) or alcohol (2). Therefore, the prognostic assessment and choice of therapeutic modalities, such as liver resection, local ablation therapy, transcatheter arterial chemoembolization (TACE), and liver transplantation strongly depends not only on the grade of cancer spread (tumor staging), but also on the grade of residual liver function (liver disease stage) (3).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population

et al. 2016

View full text Add to dashboard Cite

Background There has been no consensus as to which system, either the Cancer of the Liver Italian Program (CLIP) or the Japan Integrated Staging (JIS) system, is suitable to predict the prognosis of hepatocellular carcinoma (HCC) patients who underwent transcatheter arterial chemoembolization (TACE) as initial therapy. Purpose To retrospectively compare the usefulness of CLIP and JIS in predicting and stratifying the prognosis of HCC patients treated by TACE. Material and Methods Between 1995 and 2005, consecutive 728 patients with untreated HCC who underwent TACE in our institute were selected for this study. The survival rate and its prognostic factors were assessed by multivariate analysis. Patients were stratified according to the two systems, and their survival rates between the scores were compared. Results The mean follow-up period was 1689 days. The 1-year, 3-year, 5-year, and 10-year survival rates were 83.1%, 55.1%, 34.7%, and 12.8%, respectively. Both systems stratified the prognosis of patients well, but was slightly better in CLIP as compared to in JIS. As for multivariate factor analysis, less severe Child-Pugh classification ( P < 0.001), simple tumor morphology ( P < 0.001), absence of portal vein invasion ( P < 0.001), and lower alpha-fetoprotein (AFP) level ( P < 0.001) were suggested to be independent indicators for favorable survival rate. All of these independent factors were included in CLIP, whereas JIS lacked AFP level. Furthermore, the likelihood χ-test value was higher, and the Akaike information criterion value was lower for CLIP than for JIS. Conclusion CLIP is more suitable than JIS for predicting prognosis of patients with HCC who would undergo TACE in a Japanese population.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The appropriate timing for TACE combined with RFA for HCC is controversial [29][30][31]. Bharadwaz et al [32] suggested Figure 3. A 37-year-old man with HCC recurrence 5 months after liver transplantation.…”

Section: Discussionmentioning

confidence: 99%

Preliminary experience with direct percutaneous arterial embolisation combined with radiofrequency ablation for hypervascular HCC

Yang

Yan

Chen

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…The prognosis was closely associated with tumor relapse, tumor number, albumin (ALB), prothrombin time (PT) and platelet (PLT) count (8). Another study in a Danish tertiary liver center compared 18 cases of TACE & RFA combined treatment with 18 cases of TACE treatment alone and found that combined TACE & RFA treatment provided superior therapeutic effects (9). A meta-analysis of 21 studies with 3,073 cases showed that TACE & RFA combined treatment could significantly increase both the short-term and long-term survival rates and improve the prognosis (10).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Effect Analysis of Radiofrequency Ablation on Transarterial Chemoembolization Postoperative Residual

Shi¹,

Qiao²,

Yang³

et al. 2016

West Indian Med J

View full text Add to dashboard Cite

show abstract

Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center

Abstract: Combination therapy with RFA and TACE for unresectable HCC, compared to TACE alone, may offer a survival benefit for a selected group of patients with HCC.

Cited by 7 publications

References 23 publications

Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population

Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population

Preliminary experience with direct percutaneous arterial embolisation combined with radiofrequency ablation for hypervascular HCC

Therapeutic Effect Analysis of Radiofrequency Ablation on Transarterial Chemoembolization Postoperative Residual

Contact Info

Product

Resources

About